From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

In the phase II DESTINY-Lung01 trial, Bob T. Li, MD, PhD, MPH, and colleagues found that fam-trastuzumab deruxtecan-nxki produced durable responses in a high proportion of patients with previously treated HER2-mutant non–small cell lung cancer

New England Journal of Medicine
Advertisement
News & Literature Highlights
Advertisement
Advertisement